Edgewise Therapeutics reported net income of US$1,166.15 million in Q3 2026 and held a favorable End-of-Phase 2 meeting with the FDA that enabled submission of the STRATUS-HCM Phase 3 protocol for EDG-7500 in hypertrophic cardiomyopathy. The planned STRATUS-HCM program uses an echo independent, investigator guided dose escalation design across both obstructive and nonobstructive hypertrophic cardiomyopathy within a single global master protocol, which reflects how Edgewise Therapeutics is...
Tipranks Press Release.
Detailed price information for Edgewise Therapeutics Inc (EWTX-Q) from The Globe and Mail including charting and trades.
Detailed price information for Lexeo Therapeutics Inc (LXEO-Q) from The Globe and Mail including charting and trades.
Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.
Edgewise Therapeutics' (EWTX) EDG-7500 mechanism reveal accounts for strong clinical showing, lendin
2026-06-17. The following slide deck was published by Edgewise Therapeutics, Inc.
Detailed price information for Csl Ltd (CMXHF) from The Globe and Mail including charting and trades.
Detailed price information for Edgewise Therapeutics Inc (EWTX-Q) from The Globe and Mail including charting and trades.
Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that the CIRRUS-HCM abstract was selected for a late-breaking science presentation at the European Society of Cardiology (ESC) Congress, taking place August 28-31 in Munich, Germany. EDG-7500 is a novel, oral, selective cardiac sarcomere modulator designed to slow early contraction and improve cardiac relaxation in symptomatic HCM while preserving sys
This is the newest page. Registered accounts read further back.